Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Microbot Medical Inc.NASDAQ: MBOT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $3.03M rose 93.9% year over year, ahead of the +81.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 27.1% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +65.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.03M+27.1% QoQ
- Last fiscal yearDec 2025
- $8.25M+65.1% YoY
- LTMMar 2026
- $9.71M+81.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +93.9% | -100.0% | -193.9 pp |
| 1 year | +65.1% | -100.0% | -165.1 pp |
| 3-year CAGR | +13.9% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 8.25M USD
- Year-over-year change
- +65.1%
- 4-year CAGR
- +11.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.25M | +65.1% |
| FY2024 | 2024-12-31 | 5M | +20.9% |
| FY2023 | 2023-12-31 | 4.13M | -26.0% |
| FY2022 | 2022-12-31 | 5.58M | +3.2% |
| FY2021 | 2021-12-31 | 5.41M | — |
Selling, General & Admin vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +81.8% is the 2nd highest of 10, against a peer median of -6.4%.
- Selling, general & admin amounts to 9251.4% of revenue for MBOT, versus a peer median of 3202.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $31.21T USD | +20801703.5% | +10.7% | 10343531.1% | |
| LTM Mar 2026 | $78.19M USD | -14.1% | +20.9% | 108.1% | |
| LTM Mar 2026 | $24.75M USD | -6.4% | -9.4% | 347.5% | |
| LTM Mar 2026 | CA$20.29M CAD | -9.6% | +7.3% | — | |
| LTM Mar 2026 | $9.71M USD | +81.8% | +13.9% | 9251.4% | |
| LTM Mar 2026 | $9.52M USD | +9.5% | +20.6% | — | |
| LTM Mar 2026 | $8.48M USD | +21.4% | -17.7% | — | |
| LTM Mar 2026 | $8.11M USD | +9.0% | +0.2% | — | |
| LTM Mar 2026 | $7.9M USD | -34.1% | -17.0% | 5897.0% | |
| LTM Mar 2026 | CA$5.32M CAD | -33.6% | -36.1% | 3202.5% | |
| Peer median (excluding MBOT) | — | -6.4% | +0.2% | 3202.5% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 106K | 91K | 0 |
| Gross Profit | 0 | 0 | (106K) | (91K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.15M | 7.74M | 5.72M | 6.63M | 6.28M |
| Selling, General & Admin | 5.41M | 5.58M | 4.13M | 5M | 8.25M |
| Operating Expenses | 11.36M | 13.28M | 9.75M | 11.53M | 14.74M |
| Depreciation & Amortization | 76K | 102K | 106K | 91K | 47K |
| EBITDA | (11.24M) | (13.34M) | (10.63M) | (11.35M) | (13.1M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (11.36M) | (13.28M) | (9.86M) | (11.63M) | (14.74M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 44K | 54K | 228K | 182K | 1.29M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 44K | 113K | (885K) | 182K | 1.6M |
| Income Before Tax | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.59) | (1.81) | (1.05) | (0.73) | (0.29) |
| EPS (Diluted) | (1.59) | (1.81) | (1.05) | (0.73) | (0.29) |
| Weighted Avg Shares | 7.11M | 7.26M | 10.2M | 15.65M | 45.79M |
| Weighted Avg Shares (Diluted) | 7.11M | 7.26M | 10.2M | 15.65M | 45.79M |
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.